Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The news about Asepticsure is out and has been out for a while - I don't see this adding much. Obviously most the public has no confidence in current management's ability to capitalize on this tremendous potential- hence our current share price.
No that is why I try not to make absolute statements like this one made 18 months ago:
"There is absolutely nothing that can hinder this; nothing that can derail this; and absolutely NOTHING that can stop it. The “setbacks” are all behind us now. It’s no longer a matter of time, but a matter of fact."
This is just one example of many.
Considering some of their ridiculous predictions back in 2009/10 it's not surprising that they would be embarrassed to post anymore.
Mike – I understand that it might not do as good a job as Asepticsure cleaning a room in a scientific sense, but will it matter to a customer if the end result – percentage reduction in HAI’s – is the same? It seems to me that they currently have 2 advantages over Asepticsure: Time – they claim they only need 5 minutes a room, and cost – there is no recurring costs with Xenex as opposed to the canister cost of Asepticsure.
Very curious about Xenex. Contrary to what Dr. Shannon said it looks like they have been published in a peer reviewed journal - www.xenex.com/wp-content/uploads/2011/02/ICHE-Stibich.pdf - "Infection Control and Hospital Epidemiology publishes scientifically authoritative, clinically applicable, peer-reviewed research"
They have several cases where their customers have claimed a significant reduction in HAI's. Though the level of reduction of bacteria might not be as significant as Asepticsure it seems they are gettings the results we would hope that Aspeticsure can produce. What I can't figure out is if the product they have is working why aren't more hospitals buying it and does their tough sell have any implications for Asepticsure's marketing potential?
Lots of good news, but still some lingering issues that cause me some concern.
We haven't received FDA approval - Does that mean if they say no the whole US market is gone just like that - poof?
I'm still shocked(I'll admit I was wrong - I didn't think they would sell a single unit until it was proven) that people (Canmedical and their clients) are buying this when it hasn't yet been proven that it will reduce HAI's in the real world. For that, we need hospital testing. There is no mention that any of the first 5 will be used for that – just that more details will be given when we are closer. That sounds to me that we still have a bit of a wait for that testing to commence – not to mention the time needed to get results.
It's easy to say they should just sell their shares if you bought in at 2 cents. There are many people here who paid more than 50 cents for their shares. Telling them to sell at .16 and go away is not the answer.
They put out a PR almost 3 weeks ago saying they were completed. Now they are still several days away!!
>> When the machines are ready (several days away),
BenK - "It follows" - we don't know that (without real-life testing.) Perhaps the 65% remaining is solely caused by people entering the room after the sterilization process - if that is the case 10,000 times better won't make any difference!
>> It follows that if Xenex achieves a 35% reduction in infections, a system that removes 10,000 times more of the causes of infections will do that much more.
The 20-30% is in each individual hospital that uses Asepticsure!! It would not change if they use it in more hospitals.
Ed mentioned a 20-30% reduction for Asepticsure in the cc last June.
>> but I guess they would spend money on a machine working 100%.
Hard to say "light-years ahead" when Zenex has sales - perhaps "light-years better" would be more accurate.
However we all know that better doesn't always win e.g vhs vs. betamax.
It is instructive to see that although they have reduced infections by 35% in a hospital chain, other hospitals aren't exactly lining up to buy it - perhaps a word of caution to the overly optimistic hopes for Asepticsure sales projections.
Benk - While it sounds good that is just not how Wall Street works. They expect management to deliver on what they say. It's an every day occurrence for a company's shares to fall 3-10% just by missing an earnings projection by a couple of pennies. Investors demand dependibility - Medizone's management has not delivered that.
Any normal investor, that excludes all of us 10+ year longs :), is thinking if they can't deliver a simple picture in the promised time-frame how the heck should I trust them to deliver on much more significant issues?
>> Just what is it you would do different?
I would try to keep my word, and if unforseen circumstances prevent me from doing that I would explain why.
Also it is part of the job description to anticipate delays - don't promise what you can't deliver.
Ed has zero credibility left. In his last message he mentioned numerous events along with timelines. He has already missed the first 2. What makes anyone think he will actually make any of the others?
The first distributor announcements will come this month. - They announced 1 distributor agreement in January.
Studio quality photos of the finished AsepticSure unit will be published to the website sometime in February. - Nuttin yet.
This just continues a pattern of failing to live up to what he has promised. Wall Street likes to know they can trust a company - they don't like surprises. Even if they finally manage to get Asepticsure off the ground I believe that Ed's leadership will cost us shareholders billions in unrealized gains.
This was from Sep. 2010 - I assumed we heard about these results already when they significantly lowered the amount of time necessary to get the desired results.
>> During late September 2010...
Eli - Very little mention in 10K of any of the other possible applications that were supposed to be first to market before hospital sales.
Not exactly ordered. From the 10K:
Assuming our soft launch is successful and we are able to ramp up
production as anticipated, we currently anticipate we will deliver or have ordered a minimum of 30 machines by the end of the third quarter. While only a rough estimate, that number is based on the fact that we currently have standing orders for six machines and 20 additional units are anticipated for delivery to a single customer during calendar 2012.
It can't be Asepticsure - we have yet to prove that it reduces infections!
>>The use of hydrogen peroxide vapor has been clinically proven to substantially reduce the rate of hospital-acquired infections
Also to add - Didn't they say other channels beside hospitals e.g. bio-terrorism,clean room or food distributors etc., were expected to generate first sales? What ever happened with those tracks?
What about distributor agreements(plural) to be announced in January?
AsepticSure Patent Protection Goes Global
http://medizoneint.com/asepticsure-patent-protection-global/
San Francisco, CA February 8, 2012. Medizone International, Inc. (MZEI:OB) MZEI:QB), the company behind the AJIC peer-reviewed disinfection technology AsepticSure, announced today that it has now completed National patent application filings of its recently Granted lead patent application (Canadian Patent No 2735739). These filings apply to the United States, Mexico, Brazil, China, Japan, Korea, Singapore, the 37 countries of the European Patent Organization (EU), Great Britain, India and Australia.
AsepticSure’s clinically proven efficacy against a vast spectrum of pathogenic bacteria, fungi, spores and viruses clears the way for its use in large-scale reductions of hospital acquired infections (HAIs) in surgical centers, long-term care facilities and hospitals around the world.
It’s also the only green disinfection technology on the planet that has consistently demonstrated in peer-reviewed research, an unprecedented 100% kill-rate (> 6-log) with formidable pathogens such as C-difficile, MRSA, E coli, Pseudomonas aeruginous and VRE, the root sources of superbug infections – on both hard and soft surfaces – and without the need to remove, cover or protect the treated room’s contents.
Medizone’s lead patent was granted on November 22, 2011 by the Canadian Intellectual Property Office (patent office) for processes and systems relating to the platform technology. The Company considers this an extraordinarily strong foundational patent as it covers both the science and technology of AsepticSure.
Medizone Board Chairman and CEO, Edwin Marshall added, “Shareholders should also be delighted to know that our patent attorneys have recently received a most favorable report from the Patent Cooperation Treaty (PCT) Examiners on both the Bed Bug Application and our Bio-Terrorism Countermeasures Application for dealing with weaponized pathogens for building remediation following an attack.
“To quote, ‘The way forward to an international, favorable patentability opinion on each case seems to be clear. In no case has the examiner found any prior art of which we were not previously aware. In respect of the Anthrax case and the Bed Bugs case, there are no pertinent prior art references at all. All claims in both cases are ruled to possess both novelty and inventive step, so that they can proceed without further amendment or argument.’”
Marshall concluded, “As Medizone’s AsepticSure technology moves closer to becoming the International Standard for Disinfection of enclosed spaces, the significance of these patents to shareholder value moving forward should prove immense. It’s a great time to be involved with this Company.”
For press information on Medizone International, please contact:
Bruce Smeaton, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202 E: bruce@medizoneint.com
Medizone International, Inc. is engaged in initial production of its modular design AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being tested for bio-terrorism counter measures for building remediation.
This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
For more information, visit: www.medizoneint.com
It's not WIV that is turning people off, it's the FACTS that he clearly articulates that are! How could a company with so much potential have a share price of .12 cents? Obviously the majority of the potential investors have no confidence in the current management's ability to capitalize on this great potential.
Nice update but no mention of hospital testing?
Sure - Check posts 18078,18087 and 18095 for one example. There are others but I don't have the time or inclination to argue this point. Hopefully in the near future all these discussions and disagreements will be a thing of the past.
The fact that you are not aware doesn't make it not so.
>> I'm not aware of anyone getting "inside" info.
I understand they can't reply to every inquiry but I don't think it makes sense to consistently reply to some shareholders, sharing information with them that is not publicly available, and not with others.
I've never had a single e-mail even acknowledged by them. The only way I've ever gotten a response was when BenK forwarded my questions to Ed. They have very selected people who they will communicate with - everyone else can jump in the lake for all they care.
In my opinion he is doing a fine job in articulating why mainstream investors are not investing in a company with such great potential. Who wouldn't take a chance at .15 on this company, unless they are so disillusioned with managements ability to capitalize on the amazing potential they created.
I assume you guys are referring to something I am not privy to. Having said that, as a long-time shareholder, I think whatisvalue has legitimate questions. There is nothing wrong with some healthy skepticism in not accepting everything is fine just because people on a bb are saying they are. He certainly is entitled to voice his opinions (as long as I agree with them :)!. If management would provide more information to investors this wouldn’t be an issue.
I guess I haven't been following the patent saga closely enough. Can someone explain - have some patents been filed in Canada and some in the US?
>> 'Notice of Allowance' from the Canadian Patent Office
Jack - I understand why they didn't buy 4 up front. My question was what did they gain from the option on the remaining 3 if there was no cost savings to them, unless they have reason to believe that there will be a price increase within the next year.
I'm not assuming it - it's information I got in an e-mail from Ed.
I'm actually surprised that they made any hospital sales without having data showing a reduction in HAI's.
They did have in their FIME video a reduction claim and I finally got a clarification if that was based on test results that haven’t been published yet. Unfortunately the answer was no - it was based on the fact that everyone "thinks" it will reduce them.
I think it is a terrible idea to advertise a claim that can't be proven. It opens Medizone up to litigation if it doesn't work. Why take such a chance on jeopardizing your reputation and, in a worse case scenario our existence. If this was your only market and you were desperate for sales I can understand but considering they have other significant markets, e.g. bed bugs, where it is much easier to prove the effectiveness of Asepticsure it seems like a very risky move.
My mistake :( I was looking at this paragraph and completely missed that one of the orders was from here!
"We now have serious inquires from areas as far reaching as Central and South America, Malaysia, Indonesia, Africa and the Middle East."
I don't understand what the options are for. If they are purchasing the additional 3 at full price why the option? The only advantage I can see for the buyer is if Medizone was planning on increasing the price.
Also it's interesting to note that while foreign countries/regions were mentioned in the pr there was no mention of the good ole USA, or Europe for that matter.
>> one-year options for three additional units at the standard price of $95,000 each
Will do Go- He said he needed to check into it. Then he e-mailed that it might take a couple of days because they are at the show in Miami :)
I'm flabergasted!! If this reported sale is true, and I don't mean to cast aspersions on the varacity of Gelati's report, I will have to admit that I was wrong. Never thought someone would buy something that hasn't yet been proven to reduce HAI's.
Still trying to get confirmation on the claim in the video(1.34 mark)that it does reduce infections. Mr. Eversull said he would have to check up on that - to see if that was based on unreported testing.
Spong - Buy on the rumor, sell on the news - It has been that way since the first stock exchange opened :)
>> consistently sales on the news.
Why would you trust a suitor to determine the correct value of your own company? WIV point (as i understand it) has been to negotiate from a position of strength you need to have all pertinent information on hand.
>> If we have a suitor for our technology let them pay for it with there staff
He also mentioned that an investment banker can help with deciding sales strategies and pricing, which should be done before your first sale.
>> why would ed entertain a investment banker if we have 0 sales